Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs

To, Ho; Someno, Shuichi; Nagai, Shinya

doi:10.2460/ajvr.2005.66.113

Cited by 20 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This toxin is the essential virulence factor in the production of the characteristic lesions of PAR [7]. The method for the administration of purified P. multocida DNT (PmDNT) by the intramuscular route was used to evaluate vaccine containing the PmDNT toxoid [10,19]. Additionally, the PmDNT toxoid is considered an important antigen in vaccines against atrophic rhinitis (AR) [9,11].…”

mentioning

confidence: 99%

Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay (ELISA) using Recombinant Toxin for Detection of Antibodies against Pasteurella multocida Toxin

Takada-Iwao

Uto

Mukai

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. To facilitate the control of progressive atrophic rhinitis (PAR) of swine caused by toxigenic Pasteurella multocida, an enzymelinked immunosorbent assay (ELISA) and a serum neutralization test (NT) have recently been developed to detect antibodies against the P. multocida dermonecrotic toxin (PmDNT). However, the NT is a cumbersome and time-consuming technique. To overcome these drawbacks, we developed an indirect ELISA, using recombinant PmDNT expressed in Escherichia coli, for the detection of antibodies to PmDNT in serum samples from pigs. The practical usefulness of this ELISA was compared with the NT using serum samples obtained from experimentally infected and naturally infected pigs. In the pigs experimentally inoculated with vaccine including PmDNT toxoid, the ELISA and neutralization antibodies were detected at almost the same time, and a good correlation was demonstrated between both tests (P<0.01, R 2 =0.807). Therefore, the ELISA can be used to evaluate the immune reaction of pigs after vaccination with P. multocida toxoid. In a survey conducted on a field herd with a history of clinical AR, the seropositivity by ELISA in pigs of age 4.5-6 months was increased even though the NT was negative, and the correlation was low between the results obtained with the two tests (P<0.01, R 2 =0.38). Therefore, the results indicated that this ELISA might be a useful alternative to the NT currently used to detect the antibody to PmDNT after vaccination or infection with P. multocida.

show abstract

mentioning

confidence: 99%

Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay (ELISA) using Recombinant Toxin for Detection of Antibodies against Pasteurella multocida Toxin

Takada-Iwao

Uto

Mukai

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that vaccines contained PMT protein or PMT protein fragments are effective against AR [5][6][7][8][9]12]. In this study, an experimental AR vaccine was developed by replacing the extracted PMT components in commercial vaccines with recombinant Nterminal and C-terminal fragment of PMT expressed in E.coli.…”

Section: Discussionmentioning

confidence: 99%

“…PMT has been considered as a good candidate for vaccine development [3]. Authentic PMT or recombinant PMT or analogues thereof have good immunological effects [3][4][5][6][7][8]. It has been reported that high levels of antibodies can be produced by inoculating sows with a mixture of three recombinant PMT fragments with/without Pasteurella multocida and the antibodies could be transmitted to their offspring with good protection against PMT challenge [9].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of an Experimental Vaccine for Atrophic Rhinitis in Piglets

Gu¹,

Fan²,

Hu³

et al. 2017

J Vaccines Vaccin

View full text Add to dashboard Cite

show abstract

“…The procedures used to determine the titers of Spa antibodies in mouse and pig sera were similar to those described previously (22), with minor modifications. Briefly, polystyrene microtiter plates (96-well assay plate; Becton Dickinson, Franklin Lakes, NJ) were coated overnight at 4°C with 50 l per well of the purified His-tagged recombinant proteins rSpaA, rSpaB, rSpaC664, rSpaC427, and rSpaC253 at concentrations of 5 g/ml in bicarbonate coating buffer.…”

Section: Methodsmentioning

confidence: 99%

Immunization with Truncated Recombinant Protein SpaC of Erysipelothrix rhusiopathiae Strain 715 Serovar 18 Confers Protective Immunity against Challenge with Various Serovars

Someno

Nagai

et al. 2010

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Previously, we showed that surface protective antigen (Spa) proteins of Erysipelothrix rhusiopathiae can be classified into three molecular species-SpaA, SpaB, and SpaC-and that SpaC is the most broadly cross-protective antigen among the three Spa proteins. In this study, we examined the ability of the ␣-helical domain, which comprises the N-terminal half of SpaC, to elicit cross-protective immunity in mice and pigs. Mice actively immunized with the full-length protein (rSpaC664) or the ␣-helical domain (rSpaC427), but not the C-terminal domain (rSpaC253), were protected against challenge with E. rhusiopathiae serovars 1a, 2, 6, 19, and 18 expressing heterologous (SpaA or SpaB) and homologous (SpaC) Spas. The ␣-helical domain seemed to provide better protection than rSpaC664, although the differences did not reach statistical significance. Similarly, mice passively immunized with rabbit anti-rSpaC664 or anti-rSpaC427 sera, but not anti-rSpaC253 serum, were protected from challenge with various serovars. Pigs immunized with SpaC427 also developed specific antibodies against Spa proteins and were protected from challenge with the highly virulent heterologous E. rhusiopathiae strain Fujisawa (serovar 1a). Taken together, these results demonstrate for the first time the striking protective efficacy of the ␣-helical domain-mediated immunization in both mice and pigs, thereby highlighting its utility as the most promising candidate for the development of a safe and effective vaccine against erysipelas.

show abstract

Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs

Cited by 20 publications

References 17 publications

Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay (ELISA) using Recombinant Toxin for Detection of Antibodies against Pasteurella multocida Toxin

Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay (ELISA) using Recombinant Toxin for Detection of Antibodies against Pasteurella multocida Toxin

Evaluation of an Experimental Vaccine for Atrophic Rhinitis in Piglets

Immunization with Truncated Recombinant Protein SpaC of Erysipelothrix rhusiopathiae Strain 715 Serovar 18 Confers Protective Immunity against Challenge with Various Serovars

Contact Info

Product

Resources

About